Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design

Scott M. Leighow, Chuan Liu, Haider Inam, Boyang Zhao, Justin R. Pritchard

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Rationally designing drugs that last longer in the face of biological evolution is a critical objective of drug discovery. However, this goal is thwarted by the diversity and stochasticity of evolutionary trajectories that drive uncertainty in the clinic. Although biophysical models can qualitatively predict whether a mutation causes resistance, they cannot quantitatively predict the relative abundance of resistance mutations in patient populations. We present stochastic, first-principle models that are parameterized on a large in vitro dataset and that accurately predict the epidemiological abundance of resistance mutations across multiple leukemia clinical trials. The ability to forecast resistance variants requires an understanding of their underlying mutation biases. Beyond leukemia, a meta-analysis across prostate cancer, breast cancer, and gastrointestinal stromal tumors suggests that resistance evolution in the adjuvant setting is influenced by mutational bias. Our analysis establishes a principle for rational drug design: when evolution favors the most probable mutant, so should drug design.

Original languageEnglish (US)
Pages (from-to)3951-3963.e4
JournalCell Reports
Volume30
Issue number12
DOIs
StatePublished - Mar 24 2020

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design'. Together they form a unique fingerprint.

Cite this